BIOMEA FUSION INC. -

Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference

09 1 2024 10:02:26 提供 Nasdaq GlobeNewswire

Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219

08 1 2024 08:00:26 提供 Nasdaq GlobeNewswire

Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference

02 1 2024 15:05:00 提供 Nasdaq GlobeNewswire

Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH Annual Meeting

11 12 2023 08:25:04 提供 Nasdaq GlobeNewswire

Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts

09 12 2023 16:30:16 提供 Nasdaq GlobeNewswire

Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

08 12 2023 08:00:00 提供 Nasdaq GlobeNewswire

Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

07 12 2023 08:15:10 提供 Nasdaq GlobeNewswire

Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes

05 12 2023 07:30:23 提供 Nasdaq GlobeNewswire

Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024

27 11 2023 07:30:27 提供 Nasdaq GlobeNewswire

Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease

16 11 2023 07:30:59 提供 Nasdaq GlobeNewswire

Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

08 11 2023 15:05:51 提供 Nasdaq GlobeNewswire

Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023

02 11 2023 08:05:57 提供 Nasdaq GlobeNewswire

Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights

30 10 2023 15:01:20 提供 Nasdaq GlobeNewswire

Biomea Fusion Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)

17 10 2023 07:30:41 提供 Nasdaq GlobeNewswire

Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for BMF-219 in Type 1 Diabetes

05 10 2023 07:30:00 提供 Nasdaq GlobeNewswire

Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study

28 9 2023 07:30:00 提供 Nasdaq GlobeNewswire

Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer

31 8 2023 07:30:41 提供 Nasdaq GlobeNewswire

Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights

31 7 2023 15:01:28 提供 Nasdaq GlobeNewswire

Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association (ADA) 83rd Scientific Sessions; 100 mg Cohort 3 Demonstrated a 90% Response Rate and 70% Maintained or Improved Time in (Normal Glucose) Range, While Off-Treatment

23 6 2023 20:54:37 提供 Nasdaq GlobeNewswire

Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes at ADA 2023

20 6 2023 15:30:19 提供 Nasdaq GlobeNewswire